Title:
SHP2 INHIBITOR, AND CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/230968
Kind Code:
A1
Abstract:
Provided are an SHP2 inhibitor, and a crystal form thereof, a preparation method therefor, and a use thereof. Provided are a crystal form B of a compound as shown in formula (I), a compound as shown in formula (II) and a crystal form A thereof, a compound as shown in formula (III) and a crystal form A thereof, a compound as shown in formula (IV) and a crystal form A thereof, a compound as shown in formula (V) and a crystal form A thereof, and a compound as shown in formula (VI) and a crystal form A thereof as well as a preparation method therefor and a use thereof. The compounds and the crystal forms thereof have one or more of the following advantages: being stable in property, good in hygroscopicity, and good in bioavailability, and having good drug development prospects.
Inventors:
ZHA CHUANTAO (CN)
WAN HUIXIN (CN)
MA JINGUI (CN)
WAN HUIXIN (CN)
MA JINGUI (CN)
Application Number:
PCT/CN2022/096702
Publication Date:
December 07, 2023
Filing Date:
June 01, 2022
Export Citation:
Assignee:
SHANGHAI RINGENE BIOPHARMA CO LTD (CN)
SHANGHAI RINGENE THERAPEUTICS CO LTD (CN)
SHANGHAI RINGENE THERAPEUTICS CO LTD (CN)
International Classes:
C07D471/04; A61K31/438; A61K31/444; A61K31/4545; A61K31/519; A61P35/00; C07D401/14; C07D487/04; C07D519/00
Domestic Patent References:
| WO2020072656A1 | 2020-04-09 | |||
| WO2020108590A1 | 2020-06-04 | |||
| WO2020259679A1 | 2020-12-30 |
Foreign References:
| CN111153901A | 2020-05-15 | |||
| CN111704611A | 2020-09-25 | |||
| CN112839935A | 2021-05-25 | |||
| CN111138412A | 2020-05-12 |
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: